Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00101725 · ClinicalTrials.gov registry record · Phase 2
A Study of Crofelemer to Treat Diarrhea Irritable Bowel Syndrome
A Phase 2 study of Irritable Bowel Syndrome and Diarrhea, sponsored by Bausch Health Americas.
- Completed
- Registry status
- Phase 2
- Development phase
- 245
- Enrollment target
- 20
- Study locations
NCT00101725: Completed Phase 2 study of Irritable Bowel Syndrome and Diarrhea, sponsored by Bausch Health Americas.
NCT00101725 is a Phase 2 study of Irritable Bowel Syndrome and Diarrhea that has completed, run by Bausch Health Americas. The registered enrollment target is 245 participants, above the 139-participant average among 47 other Irritable Bowel Syndrome trials with a reported enrollment target (76% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00101725, a Phase 2 study of Irritable Bowel Syndrome and Diarrhea, has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 245 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is designed to evaluate the safety and effectiveness of an investigational drug, TRN-002 (crofelemer) to relieve the symptoms of diarrhea-predominant irritable bowel syndrome (IBS).
Conditions Studied
Interventions
- DRUG crofelemer
Study Locations (20)
California
- AGMG Clinical Research Institute - Anaheim
- Community Clinical Trials - Orange
- AGMG Clinical Research - Orange
- Institute of Healthcare Assessment, Inc. - San Diego
North Carolina
- LeBauer Research Associates, PA - Greensboro
- Medoff Medical / Vital Research - Greensboro
- Hanover Medical Specialists, PA - Wilmington
- Piedmont Medical Research Assoc., Inc. - Winston-Salem
Florida
- Consultants for Clinical Research of South Florida - Boynton Beach
- University Clinical Research DeLand - DeLand
Alabama
- Clinical Research Associates - Huntsville
Arizona
- Radiant Research Phoenix Southeast - Chandler
Arkansas
- Arkansas Gastroenterology - North Little Rock
District of Columbia
- Washington Gastroenterology - Washington D.C.
Illinois
- nTouch Research - Peoria
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 245 participants |
| Start Date | 2004-12 |
| Est. Completion | 2005-11 |
| Phase | Phase 2 |
What the finished NCT00101725 record still lists
NCT00101725 is an interventional study that assigns participants to a tested intervention. The registered 245 participants enrollment target is mid-sized for trials with a published cap, above the 139-participant average among 47 other Irritable Bowel Syndrome trials with a reported enrollment target (76% higher).
The record links to 4 conditions, with Irritable Bowel Syndrome appearing as the primary indexed condition, and to 1 intervention - of which crofelemer is the first listed.
NCT00101725 names 20 study sites across 13 states, led by California, North Carolina, Florida.
Frequently Asked Questions
What is clinical trial NCT00101725 about?
NCT00101725 is a clinical study titled "A Study of Crofelemer to Treat Diarrhea Irritable Bowel Syndrome". This study is designed to evaluate the safety and effectiveness of an investigational drug, TRN-002 (crofelemer) to relieve the symptoms of diarrhea-predominant irritable bowel syndrome (IBS).
What is the current status of trial NCT00101725?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 245 participants. The study started on 2004-12. Estimated completion is 2005-11.
What conditions does trial NCT00101725 study?
This clinical trial studies the following conditions: Irritable Bowel Syndrome, Diarrhea, Gastrointestinal Disease, Colonic Diseases.
What interventions are being tested in trial NCT00101725?
The interventions under investigation include: crofelemer (DRUG).
Who is sponsoring clinical trial NCT00101725?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00101725 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Irritable Bowel Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00101725's enrollment target sits among peer trials
245 11th of 47 higher than 37 of 47 other Irritable Bowel Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Irritable Bowel Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Psyllium in Pediatric IBS
RECRUITING · Phase 2
-
Fecal Microbiota Transplantation for IBS
RECRUITING · Phase 2
-
Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children
RECRUITING · Phase 2
-
Assessment of Psilocybin (TRP-8802) in Concert With Psychotherapy in Patients With Irritable Bowel Syndrome (IBS)
ACTIVE NOT RECRUITING · Phase 2
-
Effect of BIO-K+ on Symptoms of Irritable Bowel Syndrome
COMPLETED · Phase 2
-
A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03645928 · 245 participants · Phase 2
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
- NCT04718168 · 245 participants · NA
GORE® ENFORM Biomaterial Product Study
- NCT05145127 · 245 participants · Phase 3
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
- NCT05446259 · 245 participants
Degenerative Cervical Myelopathy Repository
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia